Shares of Vertex Pharmaceuticals Inc. climbed 15 percent Wednesday following better-than-expected results from the company's Phase III STRIVE study of VX-770, its oral medicine candidate targeting the defective protein that causes the hereditary condition cystic fibrosis (CF).